B
Bull
Bull · 25%APLS
$26.85
Scenario price
$41.030
-0.029 (-0.07%)At close
Loading chart…
- High
- 41.070
- Open
- 41.050
- VWAP
- 41.04
- Vol
- 68.61M
- Mkt Cap
- 5.04B
- Low
- 41.030
- Amount
- 2.82B
- EV/EBITDA, TTM
- 52.52
Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system. SYFOVRE (pegcetacoplan injection) is the Company’s approved treatment for geographic atrophy secondary to age-related macular degeneration (GA). Its EMPAVELI (pegcetacoplan) is for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Its Aspaveli (pegcetacoplan) for the treatment of adults with PNH who are anemic after treatment with a C5 inhibitor for at least three months. Systemic pegcetacoplan has also been approved for the treatment of PNH in Japan, Saudi Arabia, Australia, the United Kingdom and other jurisdictions. Systemic pegcetacoplan is marketed under the trade name EMPAVELI in the United States, Saudi Arabia and Australia and Aspaveli in the European Union, Japan and the United Kingdom.
Analyst Ratings (3)
-22.76% downside
Buy
3 Buy
0 Hold
0 Sell
Current: 41.03
Low
19.00
Average
31.69
High
48.00
Wells Fargo
Equal Weight
$41
2026-04-17
Wells Fargo
2026-04-17
Price Target
$41
Equal Weight
RBC Capital
Sector Perform
$41
2026-04-07
RBC Capital
2026-04-07
Price Target
$41
Sector Perform
Mizuho
Neutral
$41
2026-04-02
Mizuho
2026-04-02
Price Target
$41
Neutral
Roth Capital
Neutral
$41
2026-04-02
Roth Capital
2026-04-02
Price Target
$41
Neutral
JPMorgan
Neutral
$41
2026-04-01
JPMorgan
2026-04-01
Price Target
$41
Neutral
Valuation Metrics
The current forward P/E ratio for Apellis Pharmaceuticals Inc (APLS) is 46.30, compared to its 5-year average forward P/E of -24.34.
Alphio AI Price Scenarios for APLS
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding APLS
Events Timeline
News
8.506-05stocktwitsPharmaceutical Giants Accelerate Acquisitions to Offset Patent Cliffs
8.505-14GlobenewswireBiogen Completes Acquisition of Apellis Pharmaceuticals
8.505-14NewsfilterBiogen Completes Acquisition of Apellis Pharmaceuticals
4.505-07moomooS&P Dow Jones Indices: Bright Horizons Family Solutions and Remitly Global to be Added to S&P SmallCap 600
4.505-06NASDAQ.COMAnalysis of XBI ETF Trading Dynamics
APLS FAQ — answered by Alphio AI
Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system. SYFOVRE (pegcetacoplan injection) is the Company’s approved treatment for geographic atrophy secondary to age-related macular degeneration (GA). Its EMPAVELI (pegcetacoplan) is for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Its Aspaveli (pegcetacoplan) for the treatment of adults with PNH who are anemic after treatment with a C5 inhibitor for at least three months. Systemic pegcetacoplan has also been approved for the treatment of PNH in Japan, Saudi Arabia, Australia, the United Kingdom and other jurisdictions. Systemic pegcetacoplan is marketed under the trade name EMPAVELI in the United States, Saudi Arabia and Australia and Aspaveli in the European Union, Japan and the United Kingdom. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
3 analysts cover APLS: 3 rate it Buy, 0 Hold and 0 Sell. The average price target is 31.69.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.